David is currently a Managing Director of VIMAC Milestone Medica, LP, an early stage life science fund with VIMAC Ventures, LLC, a Boston based venture capital firm. The fund invests in the pharmaceutical, medical device and instrument sectors with start-up companies based on emerging technologies from leading academic institutions. At VIMAC, David participates in the formation and capitalization of companies, and working closely with the Fund’s portfolio companies, is involved in licensing transactions, collaborative research agreements and clinical trial activities.
Before joining VIMAC, David had over twenty-five years of business development and new venture experience including with Colgate-Palmolive in their corporate M&A group, as well as CFO of a Colgate subsidiary and Director of M&A, Industrial Products for Colgate’s billion dollar health care and industrial specialty subsidiary, The Kendall Company. At Kendall, David developed and implemented a strategic growth plan through acquisition, and later went on to start up and run an in-house industrial polymer membrane business, which he grew, spun off and successfully sold to a large multinational company. Most recently, before joining VIMAC, David was a General Partner with Wellfleet Investments in Boston, a private equity placement firm that developed a portfolio of emerging life science technologies from leading medical research institutions. While at Wellfleet, he also served as CEO of a medical clinic established by the firm based on an advanced gastrointestinal rehabilitation therapy developed at a Harvard teaching hospital.
David is a graduate of Syracuse University (’70, BA, Political Science) and is a member of the Board of Visitors for SU’s College of Arts and Sciences. He holds an MBA from Pace University. He lives in Newton, MA with his wife and two daughters.